Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking β-blockers

Pharmacotherapy

Volumn 27, Issue 5, 2007, Pages 684-690

  Brooks, Tyson W A ^a,d   Creekmore, Freddy M ^b   Young, David C ^b   Asche, Carl V ^b   Oberg, Brian ^b   Samuelson, Wayne M ^c  

^a Louis College of Pharmacy ^*  (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

blocker; Asthma; Cardioselective; Chronic obstructive pulmonary disease; COPD; Hospitalization; Nonselective

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARVEDILOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LABETALOL; LEUKOTRIENE; METHYLXANTHINE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NADOLOL; PROPRANOLOL DERIVATIVE; SOTALOL; TIMOLOL;

ADULT; ARTICLE; ASTHMA; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; EMERGENCY CARE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ASTHMA; COHORT STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART DISEASES; HOSPITALIZATION; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34247877600     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.5.684     Document Type: Article

References (15)

1. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
2. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
3. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HP). JAMA 2000;283:1295-302.
4. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
5. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult [online exclusive article]. Circulation 2005;112:el54-235. Available from http://circ.ahajournals.org/cgi/content/full/112/12/e154.
6. Self T, Soberman JE, Bubla JM, Chaffin CC. Cardioselective β-blockers in patients with asthma and concomitant heart failure or history of myocardial infarction: when do benefits outweigh risks? J Asthma 2003;40:839-45.
7. GlaxoSmithKline. Coreg (carvedilol) package insert. Research Triangle Park, NC; 2005.
8. AztraZeneca. Toprol-XL (metoprolol succinate) package insert. Wilmington, DE; 2005.
9. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002;137:715-25.
10. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002;21:1290-5.
11. Barnett MJ, Milavetz G, Kaboli PJ. β-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease. Pharmacotherapy 2005;25:1550-9.
12. National Center for Health Statistics. Health, United States, 2005, with chartbook on trends in the health of Americans. Hyattsville, MD, 2005:239-40.
13. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26:1585-95.
14. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66:594-601.
15. Walle T, Walle K, Mathur RS, Palesh YY, Conradi EC. Propranolol metabolism in normal subjects: association with steroid hormones. Clin Pharmacol Ther 1994;56:127-32.